Piramal Critical Care (PCC), a division of Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), today announced the U.S. launch of Erythromycin Lactobionate for Injection, USP, 500 mg Single-Dose Vial. This product further expands PCC's growing portfolio of generic injectables.
Peter DeYoung, Chief Executive Officer, Piramal Global Pharma, commented: “We are pleased to announce the launch of Erythromycin Lactobionate for Injection, USP, as we continue to strategically expand our U.S. hospital products portfolio. This launch reflects our commitment to providing healthcare professionals with access to essential injectable medicines backed by Piramal's quality standards. Through continued portfolio expansion, we remain focused on supporting hospitals and helping address the evolving needs of patients and healthcare providers.”
The launch of Erythromycin Lactobionate for Injection, USP, marks the latest addition to Piramal Critical Care's expanding U.S. generic injectables portfolio. PCC continues to invest in delivering a broad range of essential medicines to hospitals and health systems, complementing its established portfolio of critical care, anesthesia, and injectable products.
For full prescribing information on Erythromycin Lactobionate for Injection, USP, please click here: Full prescribing information available here.
